about
Physiology and pathophysiology of respiratory mucosa of the nose and the paranasal sinuses.Effect of Native Gastric Mucus on in vivo Hybridization Therapies Directed at Helicobacter pylori.Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design.Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus.Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of conflicting data and opinions.Biomimetic nanowire coatings for next generation adhesive drug delivery systemsPharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting.Nanotechnology approaches for inhalation treatment of fibrosis.Nanoengineered surfaces enhance drug loading and adhesion.Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.Molecular dynamics simulations of water/mucus partition coefficients for feeding stimulants in fish and the implications for olfaction.Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.Berberine-loaded targeted nanoparticles as specific Helicobacter pylori eradication therapy: in vitro and in vivo study.Modulating Vibrio cholerae quorum-sensing-controlled communication using autoinducer-loaded nanoparticlesBuccal delivery systems.Enema ion compositions for enhancing colorectal drug delivery.Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers.Targeted delivery of liquid microvolumes into the lung.A review on bioadhesive buccal drug delivery systems: current status of formulation and evaluation methodsSemi-interpenetrating network (sIPN) gelatin nanofiber scaffolds for oral mucosal drug deliveryPolymers in the gut compress the colonic mucus hydrogel.Mathematical modeling of molecular diffusion through mucus.Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues.Engineering strategies to enhance nanoparticle-mediated oral delivery.Critical evaluation of permeation enhancers for oral mucosal drug delivery.Biomagnetic methods: technologies applied to pharmaceutical research.Advances in mucoadhesion and mucoadhesive polymers.Protein transport across the small intestine in food allergy.Self-emulsifying drug delivery systems in oral (poly)peptide drug delivery.Extracellular vesicles in blood, milk and body fluids of the female and male urogenital tract and with special regard to reproduction.Challenges in nasal drug absorption: how far have we come?The Mucus Barrier to Inhaled Gene Therapy.Lipid-based nanocarriers for the oral administration of biopharmaceutics.A Model for the Transient Subdiffusive Behavior of Particles in Mucus.The particle in the spider's web: transport through biological hydrogels.Disruption of the mucus barrier by topically applied exogenous particlesA vaginal drug delivery model.Formulation and evaluation of floating mucoadhesive alginate beads for targeting Helicobacter pylori.DNA diffusion in mucus: effect of size, topology of DNAs, and transfection reagents.
P2860
Q24634722-F52749B5-971D-48F0-AFE8-665872781916Q27317349-27D6FAA9-A5ED-431D-86DB-25816B4B8960Q30375160-C982DFF8-F0FC-43C2-9C43-34F24CAA3749Q30478934-D300D1B7-E8F7-48AC-BBB7-0B79419D67C7Q30887604-3F7AD988-31B3-4C77-9EFD-DF56D3A3D875Q33669893-842145F6-7B8A-465E-A16A-6484C51A96CEQ33888718-C0CD25E0-B206-4613-8344-F9032E008758Q34339313-CCE25437-760B-4C84-B6B8-3D92B0E00FC8Q34449624-CC1D7E42-D7B8-4740-91A3-B97F30DAED67Q34647813-6301E4FF-B128-409C-ADC7-2B7B895D89F4Q34834065-9063FF12-8E27-4465-9DF8-AB4E5A67899FQ34983895-2705FB89-857B-4E48-9062-3C10A845FF19Q35077568-8244553A-B068-4A01-BFFD-03D04F7E3253Q35236166-50F1D733-9DD8-48D6-B995-5F8AC2B90E90Q35328795-B73714E9-1F1A-41A2-BF31-F2986974A76BQ35564695-F907354A-0C02-4162-B05D-FB49D51BE78BQ35691007-7F79CF1C-35E0-4680-B1A1-38E984CD2E7FQ35877982-8CCA7871-5186-4DFE-9870-9F09A0910D2EQ36078988-23FE2139-C90C-4647-AFCB-14E797126EE1Q36215627-C1401058-C6A3-4B0D-A7CC-FEC66F9E3A6AQ36756072-C3910008-6C27-4B1B-A05F-571857D21083Q37065202-CB16CBA7-6603-43BE-886B-3B64C6AA0CF5Q37107366-1A63D105-1F27-42AB-965B-E0B12A58E42FQ37153923-135C6337-F60A-44F2-A0D8-F53229448514Q37328673-54A48DA8-0308-407D-817C-E43BC9FB0594Q37575468-B4D18E17-150E-4310-B27C-43613B643388Q37800414-93A1E4E3-A305-4895-A603-79634D146648Q37824309-29507851-0670-4704-B50C-F29A5ADF7D00Q38176292-F7D89B76-3BDC-420E-A858-C7546034E59AQ38610269-6F76E099-0CB1-4B2B-950D-C2129FF2554FQ38837378-A3F65C1B-612D-4A22-858E-DBAA543B57F4Q38842805-F57A645C-9492-4D9F-A791-350E49052F56Q38959100-B0BF83EC-A135-4A92-8936-31D176124553Q38990887-68840090-1E96-4933-9088-A55013505611Q39026756-35231FD4-4A65-4B50-9BEF-17573183878EQ39350747-7950E63F-9D04-4A7A-8B08-861A79B84607Q40732392-69F63D05-B4B2-4864-A688-A71F664888C2Q40757704-7712F0F5-D893-4ED3-AEA1-13E293ACC2F1Q41605558-9381B27D-D943-47FF-B5C7-EA3CEA92C3F8Q41666565-90E74F9A-0A23-4676-8434-ABA4B7B57EFE
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Drug transfer through mucus.
@ast
Drug transfer through mucus.
@en
Drug transfer through mucus.
@nl
type
label
Drug transfer through mucus.
@ast
Drug transfer through mucus.
@en
Drug transfer through mucus.
@nl
prefLabel
Drug transfer through mucus.
@ast
Drug transfer through mucus.
@en
Drug transfer through mucus.
@nl
P2093
P1476
Drug transfer through mucus.
@en
P2093
Donovan MD
Flanagan DR
Khanvilkar K
P304
P356
10.1016/S0169-409X(01)00115-6
P407
P577
2001-06-01T00:00:00Z